{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T20:51:23Z","timestamp":1782420683772,"version":"3.54.5"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The occurrence of atrial fibrillation is often accompanied by myocardial fibrosis. An increasing number of studies have shown that intestinal flora is involved in the occurrence and development of a variety of cardiovascular diseases. This study explores the relationship between changes in the structure and function of intestinal flora and the progression of myocardial fibrosis in patients with persistent atrial fibrillation.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Serum and stool samples were collected from 10 healthy people and 10 patients with persistent atrial fibrillation (PeAF), and statistical analyses were performed on the subjects' clinical baseline conditions. ELISA was used to measure the levels of carboxy-terminal telopeptide of type I collagen (CTX-I), propeptide of type I procollagen (PICP), procollagen III N-terminal propeptide (PIIINP), fibroblast growth factor-23 (FGF-23), and transforming growth factor-beta 1 (TGF-\u03b21) in serum. Through 16S rRNA sequencing technology, the structural composition of the intestinal flora was detected and analyzed. In addition, metabolomics data were analyzed to determine the differences in the metabolites produced by the intestinal flora of the subjects.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> By comparing the baseline data of the subjects, it was found that compared with those of the control group, the levels of creatinine (CRE) and serum uric acid (SUA) in the serum of PeAF patients were significantly increased. In addition, we found that the levels of CTX-I, PICP, PIIINP, and TGF-\u03b21 in the serum of PeAF patients were significantly higher than those of the control group subjects. Although the control and PeAF groups exhibited no significant differences in the \u03b1 diversity index, there were significant differences in the \u03b2 diversity indexes (Bray-Curtis, weighted UniFrac and Anosim). At the phylum, family and species levels, the community structure and composition of the intestinal flora of the control group and those of the PeAF group showed significant differences. In addition, the compositions of the intestinal metabolites in the two different groups of people were significantly different. They were correlated considerably with PIIINP and specific communities in the intestinal flora.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Pathologically, PeAF patients may have a higher risk of myocardial fibrosis. Systematically, abnormal changes in the structure and composition of the intestinal flora in PeAF patients may lead to differences in intestinal metabolites, which are involved in the process of myocardial fibrosis through metabolite pathways.<\/jats:p>","DOI":"10.3389\/fnut.2021.702085","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T07:13:59Z","timestamp":1629702839000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Changes in Intestinal Flora Structure and Metabolites Are Associated With Myocardial Fibrosis in Patients With Persistent Atrial Fibrillation"],"prefix":"10.3389","volume":"8","author":[{"given":"Langsha","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanyan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00071-20","article-title":"Different types of atrial fibrillation share patterns of gut microbiota dysbiosis[J]","author":"Zuo","year":"2020","journal-title":"mSphere."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1093\/eurheartj\/ehz786","article-title":"Atrial fibrillation and cardiac fibrosis","volume":"41","author":"Sohns","year":"2020","journal-title":"Eur Heart J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/europace\/euaa009","article-title":"Atrial fibrosis as a dominant factor for the development of atrial fibrillation: facts and gaps","volume":"22","author":"Xintarakou","year":"2020","journal-title":"Europace"},{"key":"B4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijcard.2016.06.144","article-title":"Assessment of atrial fibrosis for the rhythm control of atrial fibrillation","volume":"220","author":"Begg","year":"2016","journal-title":"Int J Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.14336\/AD.2020.0604","article-title":"Roles of biomarkers in myocardial fibrosis","volume":"11","author":"Ding","year":"2020","journal-title":"Aging Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.athoracsur.2020.05.156","article-title":"Matrix metalloproteinases increase because of hypoperfusion in obstructive hypertrophic cardiomyopathy","volume":"111","author":"Bi","year":"2021","journal-title":"Ann Thorac Surg."},{"key":"B7","doi-asserted-by":"publisher","first-page":"632260","DOI":"10.3389\/fphys.2021.632260","article-title":"An overview of FGF-23 as a novel candidate biomarker of cardiovascular risk","volume":"12","author":"V\u00e1zquez-S\u00e1nchez","year":"2021","journal-title":"Front Physiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"19502","DOI":"10.1002\/jcp.28548","article-title":"FGF23 regulates atrial fibrosis in atrial fibrillation by mediating the STAT3 and SMAD3 pathways","volume":"234","author":"Dong","year":"2019","journal-title":"J Cell Physiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"916","DOI":"10.2174\/0929867324666170727104930","article-title":"Post cardiovascular surgery atrial fibrillation. biomarkers determining prognosis","volume":"26","author":"Manfrini","year":"2019","journal-title":"Curr Med Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijmm.2020.4842","article-title":"Atrial fibrosis underlying atrial fibrillation (Review)","volume":"47","author":"Li","year":"2021","journal-title":"Int J Mol Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"5394096","DOI":"10.1155\/2020\/5394096","article-title":"Implication of gut microbiota in cardiovascular diseases","volume":"2020","author":"Zhou","year":"2020","journal-title":"Oxid Med Cell Longev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/j.jacc.2019.03.024","article-title":"Intestinal microbiota in cardiovascular health and disease: JACC state-of-the-Art review","volume":"73","author":"Tang","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"giz058","DOI":"10.1093\/gigascience\/giz058","article-title":"Disordered gut microbiota and alterations in metabolic patterns are associated with atrial fibrillation","volume":"8","author":"Zuo","year":"2019","journal-title":"GigaScience"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1128\/mSystems.00422-19","article-title":"Duration of persistent atrial fibrillation is associated with alterations in human gut microbiota and metabolic phenotypes","author":"Zuo","year":"2019","journal-title":"mSystems."},{"key":"B15","doi-asserted-by":"publisher","first-page":"13356","DOI":"10.1111\/jcmm.15959","article-title":"Shifts in gut microbiome and metabolome are associated with risk of recurrent atrial fibrillation","volume":"24","author":"Li","year":"2020","journal-title":"J Cell Mol Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.2337\/db19-0153","article-title":"Assessment of causal direction between gut microbiota-dependent metabolites and cardiometabolic health: a bidirectional mendelian randomization analysis","volume":"68","author":"Jia","year":"2019","journal-title":"Diabetes."},{"key":"B17","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1186\/s12864-020-06944-w","article-title":"Metagenomic data-mining reveals enrichment of trimethylamine-N-oxide synthesis in gut microbiome in atrial fibrillation patients","volume":"21","author":"Zuo","year":"2020","journal-title":"BMC Genomics."},{"key":"B18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41569-018-0108-7","article-title":"Dietary metabolism, the gut microbiome, and heart failure","volume":"16","author":"Tang","year":"2019","journal-title":"Nat Rev Cardiol."},{"key":"B19","first-page":"71","article-title":"New ESC\/ EACTS Guidelines for the management of atrial fibrillation[J]","volume":"3","author":"Agewall","year":"2017","journal-title":"Eur Heart J Cardiovas Pharmacother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.hrthm.2014.04.003","article-title":"Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis","volume":"11","author":"Tamariz","year":"2014","journal-title":"Heart Rhythm."},{"key":"B21","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/nep.12727","article-title":"Reduced kidney function is a risk factor for atrial fibrillation","volume":"21","author":"Laukkanen","year":"2016","journal-title":"Nephrology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.2215\/CJN.04060318","article-title":"Incident atrial fibrillation and the risk of stroke in adults with chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project","volume":"13","author":"Carrero","year":"2018","journal-title":"Clin J Am Soc Nephrol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41440-018-0144-z","article-title":"Gut microbiota and inflammation in chronic kidney disease and their roles in the development of cardiovascular disease","volume":"42","author":"Onal","year":"2019","journal-title":"Hypertens Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00380-020-01669-y","article-title":"Gut microbial composition in patients with atrial fibrillation: effects of diet and drugs","volume":"36","author":"Tabata","year":"2020","journal-title":"Heart Vessels."},{"key":"B25","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ehf2.12155","article-title":"Heart failure is associated with depletion of core intestinal microbiota","volume":"4","author":"Luedde","year":"2017","journal-title":"ESC Heart Fail."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.3748\/wjg.v23.i25.4548","article-title":"Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis","volume":"23","author":"Bajer","year":"2017","journal-title":"World J Gastroenterol."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.11.006","article-title":"Alterations in the duodenal fluid microbiome of patients with pancreatic cancer[J]","author":"Kohi","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41598-017-18756-2","article-title":"Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients","volume":"8","author":"Cui","year":"2018","journal-title":"Sci Rep."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/ehaa946.0861","article-title":"The relationship between the key markers of myocardial fibrosis and gut microbiota composition in patients with heart failure and preserved ejection fraction","author":"Kaburova","year":"2020","journal-title":"Eur Heart J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3892\/ijmm.2020.4674","article-title":"Gut microbiota metabolites as integral mediators in cardiovascular diseases (Review)","volume":"46","author":"Zhu","year":"2020","journal-title":"Int J Mol Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1042\/BCJ20200429","article-title":"Heart failure and the glutathione cycle: an integrated view","volume":"477","author":"Bachhawat","year":"2020","journal-title":"Biochem J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/cvr\/cvy187","article-title":"OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction","volume":"114","author":"van der Pol","year":"2018","journal-title":"Cardiovasc Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"H871","DOI":"10.1152\/ajpheart.00362.2016","article-title":"Endoplasmic reticulum stress increases brain MAPK signaling, inflammation and renin-angiotensin system activity and sympathetic nerve activity in heart failure","volume":"311","author":"Wei","year":"2016","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e0159682","DOI":"10.1371\/journal.pone.0159682","article-title":"Inhibition of the unfolded protein response mechanism prevents cardiac fibrosis","volume":"11","author":"Groenendyk","year":"2016","journal-title":"PLoS ONE."},{"key":"B35","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3390\/ijms21030891","article-title":"The pathogenic role of very low density lipoprotein on atrial remodeling in the metabolic syndrome","volume":"21","author":"Lee","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1161\/CIRCRESAHA.116.306842","article-title":"Lipid use and misuse by the heart","volume":"118","author":"Schulze","year":"2016","journal-title":"Circul Res."}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2021.702085\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T07:14:01Z","timestamp":1629702841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2021.702085\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":36,"alternative-id":["10.3389\/fnut.2021.702085"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2021.702085","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,23]]},"article-number":"702085"}}